<DOC>
	<DOCNO>NCT00619697</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate efficacy blood glucose control type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety Biphasic Insulin Aspart 30 Combination With Metformin Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes least 6 month Insulin naive . Short term insulin treatment ( 7 day less within last 6 month ) allow Previous treatment oral antidiabetic drug least 4 month Judged investigator eligible insulin analogue plus oral antidiabetic drug treatment regimen BMI 40 kg/m2 HbA1c 712 % Able willing perform selfplasma glucose monitor The receipt investigational drug within 4 week screen A history drug alcohol abuse within last 12 month Severe , uncontrolled hypertension Known suspect allergy trial product relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>